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INTRODUCTION 
 
          In a tropical country like India, infections contribute to a majority 
of morbidity and mortality. Sepsis and secondary multi organ failures 
continue to challenge the health system. There continues to be global 
demand to improve the medical care to tackle such conditions. Scoring 
systems have been formulated to assess the severity of critical illnesses 
including sepsis and they provide prognostic information to the treating 
physicians. 
          These severity scores help in stratifying the patients and facilitating 
the prediction of disease outcomes based on certain variables. With the 
aid of such evaluation system we orient the limited resources towards 
more suitable patients. These scoring systems have the following merits  
 Objective evaluation of the patient 
 Improved triage system 
 Improved therapeutic decision making 
 Easier medical administration 
 Better Medical auditing  
 Use in randomised controlled studies and research 
 
One of the most widely used severity of illness score is the 
APACHE II score (Acute physiology age chronic health evaluation 
score). This score was first formulated by William Knaus and others at 
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George Washington University Medical Centre in 1981 and it has 
continued to remain as valuable tool in evaluating accurately the severity 
of critical illnesses. The SOFA score (Sequential organ failure assessment 
score), another prognostication score  was introduced in 1994 and is 
based on the degree of organ dysfunction.  
A study by Q Qiao et al comparing the APACHE 2and SOFA 
score in critically ill elderly patients showed that SOFA had  a better 
predictive capacity of mortality than APACHE 2. 
Another study by K.S.Abinandan et al also showed that serial 
SOFA was a better mortality indicator in cases of sepsis and MODS. 
However studies by K.M. Ho, K.Y. Lee et al showed that 
APACHE II score was a better predictor of mortality than SOFA score 
          So in this observational study, I chose to assess the presenting 
APACHE II score and SOFA score of patients admitted with sepsis with 
multi organ dysfunction syndrome and compare them both as predictors 
of mortality. 
  
 
AIMS  
AND  
OBJECTIVES 
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AIM AND OBJECTIVES 
 
To determine and compare APACHE II score and SOFA score as 
predictors of mortality in patients admitted with sepsis and MODS. 
 
 
  
  
 
REVIEW  
OF  
LITERATURE 
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REVIEW OF LITERATURE 
SEPSIS  
Sepsis is a clinical syndrome that occurs as a complication of a 
serious infection and it has a significant associated morbidity and 
mortality. The focus of infection induces a cytokine storm that produces  
a spectrum of systemic insults like generalised vasodilatation , increased  
capillary permeability and leucocyte  infiltration , finally culminating in 
widespread tissue damage1,2,3,4.  Severe sepsis can  result in a condition 
termed “multi organ dysfunction syndrome (MODS)” which has a high 
mortality even in developed countries. Despite the significant medical 
advances in the recent times severe sepsis continues to remain a killer 
disease5,6. 
 
Sepsis is a condition with varied manifestations and is turning out 
to be a major challenge to the health care providers. An improved 
understanding of the etiology and pathogenesis of sepsis along with its  
early recognition and early institution of evidence based treatment 
strategies is a pressing need. The definitions, incidence, etiopathogenesis 
and outcomes are discussed in the following sections. 
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HISTORICAL ASPECTS 
 
The word sepsis is assumed to be derived from the Greek word 
“sipsi” which means “to  make rotten ” 7,8. There are ancient manuscripts 
like the Edwin Smith papyrus of Egypt which document the suppurative 
lesions, especially those that followed the traumatic wounds and their 
systemic manifestations9,10. 
 
Hippocrates assumed that sepsis is the process of rottening of flesh 
and festering of wounds and that it is the pathway leading to generation 
of foul air in swamps. Galen had a different point of view. He proposed 
that sepsis aids wound healing. At arond 1000 BC , Ibn Sina had noted 
that fever was related to “ putrefaction of blood ” 11,12,13,14. 
 
In the early seventeenth century Hermann Boerhave proposed that 
sepsis was probably mediated by the toxic substances present in air.  In 
the nineteenth century the understanding of sepsis improved when 
Semmelweis demonstrated the co-relation between contaminated hands 
and puerperal sepsis. He realised that a simple procedure like hand 
washing with chlorinated lime solution before a gynaecological 
examination would reduce the chances of puerperal sepsis15,16,17. 
Subsequently the study of sepsis was taken forward by the pioneering 
works of Louis Pasteur and Robert Koch18,19,20. An English surgeon , 
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Joseph Lister made landmark studies regarding the anti septic 
management with carbolic acid 20,21. The German physicians Lennhartz 
and Schotmuller proposed that sepsis spreads out into the blood stream 
from the primary site via the bacterial toxins rather than the bacteria per 
se 22,23. 
 
In the late nineteen sixties , Asbough et al discovered that severe 
sepsis could result in  florid inflammatory response , particularly  in the 
respiratory system thereby producing the  diffuse alveolar infiltrates of 
the  Adult Respiratory Distress Syndrome ( ARDS ) 24,25.  Similar studies 
proved that sepsis occurs secondary to a dysregulated immune response 
and not merely due to the direct toxic effects of the invading microbes. 
With more path breaking discoveries of the various micro organisms and 
a better armamentarium of antibiotics, the management of sepsis has 
transformed significantly. In 1991 an international consensus conference 
was convened by the American College Of Chest Physicians (ACCP) and 
the Society Of  Critical Care  Medicine (SCCM ) to define the spectrum 
of sepsis and allied conditions. This was subsequently revised in 
200126,27. 
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INCIDENCE 
The annual global incidence and mortality of sepsis is estimated to 
be 13 million and 4 million respectively. The mortality rates of severe 
sepsis is as high as 50%. The global incidence of sepsis and its 
complications show a consistently rising trend on account of the  
 
1. Aging population  
2. Multiple comorbid conditions  
3.  increased immunosuppressive states  
4. Expanding  spectrum of micro organisms.  
 
Sepsis, as a cause of mortality ranks much higher than the other 
major killer diseases as illustrated by the following picture28,29 
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INCIDENCE OF SEPSIS COMPARED WITH INCIDENCE 
OF OTHER MAJOR DISEASES 
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DEFINITIONS 
 Based on the consensus among international experts specific 
definitions of sepsis and allied conditions have been formulated. 
SIRS or systemic inflammatory response syndrome may be defined 
as the presence of two or more of the following parameters 
 
1) Temp < 36 or >38.3 degree Celsius 
2) Heart rate > 90 
3) Respiratory rate > 20 
4) WBC count > 12, 000 or < 4,000 or band forms more than 
10 % 
 
Some experts advocate the inclusion of two more criteria namely 
acute onset of altered sensorium and increased plasma glucose30,31,32 . 
 
The term infection refers to the presence of micro organisms in an 
otherwise normally sterile body cavity or fluid (eg Urinary Tract ) or the 
presence of an inflammatory  response to microbes in body cavity or fluid 
that normally harbour micro organisms ( eg GIT ) 33,34. 
 
Sepsis may be defined as the presence of two or more criteria of 
SIRS in the context of a documented or clinically suspected infection . 
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But the diagnostic criteria of sepsis was further modified in  2001 - 
international conference convened by the Society Of Critical Care 
Medicine (SCCM), European Society of Intensive Care Medicine 
(ESICM), American College Of Physicians (ACCP) , American Thoracic 
Society (ATS) and Surgical Infection Society (SIS). It includes the 
following parameters, as shown in the following table 
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Septic shock may be defined as the presence of persistent 
hypotension in spite of adequate fluid resuscitation. 
 
MODS or Multi Organ Dysfunction Syndrome may be defined as 
the clinical syndrome which is associated with progressive and 
potentially reversible dysfunction of two or more organ systems. 
 
Thus these entities are a part of the continuous spectrum of sepsis. 
THE SPECTRUM OF SEPSIS AND ASSOCIATED MORTALITY 
 
 
 
  
13 
 
SEPSIS – A DISEASE CONTINUUM 
 
 
 
PATHOPHYSIOLOGY OF SEPSIS 
Sepsis occurs as a result of the complex interplay between the 
infective organism and the host immune system. The innate immune 
system which forms the first tier of defence against the invading microbes 
is chiefly responsible for the unregulated inflammatory response that 
leads to sepsis. The innate immune system is comprised of the 
monocytes, macrophages, natural killer cells , endothelial cells and the 
dendritic cells35,36,37.  When the micro organism enters the body , it 
stimulates this  non specific innate immune response via the  Toll like 
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receptors ( TLR ). These receptors are so called since they resemble the 
toll receptors found in Drosophila. 
The TLR s attach to proteins called the Pathogen Associated 
Molecular Patterns ( PAMP ) which are highly conserved sequences 
present in the various micro organsisms. The PAMPs  are usually 
comprised of lipo-polysaccharides  or LPS ( in Gram negative organisms) 
and petidoglycans ( in Gram positive organsisms ). The TLR then sends 
intra cellular signals to initiate the activation of transcription factors like 
the nuclear factor kappa b (NF KB). Subsequently there occurs 
production of inflammatory molecules like the interleukins (IL-1 , 6 , 8 ) , 
tumor necrosis factor alpha , cyclo oxygenases and prosta glandins.  Then 
there is a secondary adaptive immune response mediated by the T 
lymphocytes and B lymphocytes. The interaction between the TLR and 
the PAMPs are depicted in the following picture 
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There are more than 10 TLRs each having an affinity for a 
different microbial antigen. Of these the most important is the TLR 4 
which binds to the lipopolysaccharide component of Gram negative 
organisms and thus plays a vital role in the pathogenesis of Gram 
negative septicemia. It is also to be noted that even endogenous 
substances like heparin sulphate , hyaluronate , fibronectin , heat shock 
proteins , fibrinogen and certain polymeric sugars may also stimulate the 
TLR pathway. This explains the development of a systemic inflammatory 
response even in the absence of an infection in conditions like 
pancreatitis38,39,40. Some of the common TLRs and their specific ligands 
are illustrated in the subsequent figure.  
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The invading micro organsim interacts with  innate immunity, 
adaptive immunity, the vascular endothelium and the coagulation 
pathways to bring about the septic response. 
 
PATHOGENESIS OF SEPSIS 
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ROLE OF VASCULAR ENDOTHELIUM 
The vascular endothelium has an important role in the pathogenesis 
of sepsis. The endothelial cells may be stimulated either directly by the 
bacteria or by means of the bacterial products. The response of the 
endothelium depends on the age of the patient , gender , co-morbid 
conditions , host genetic factors and on the characteristics of the invading 
micro organism.  Impairment of the endothelial function results in 
morphological and functional changes which result in the following 
effects 
• Uncontrolled release of vaso active substances like nitric oxide 
and prostacyclins 
• Hyper reactivity of the vascular smooth muscles in response to 
vaso constrictive agents 
• Adhesion and Migration of leucocytes 
• Platelet activation and aggregation 
• Imbalance between pro coagulants and anti coagulants 
• Increased pro apoptotic substances 
• Loss of barrier function 
Thus the septic response is secondary to a complex interaction 
between the components of the microbe (eg – Lipo polysaccharides , 
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peptide glycans) and host factors (innate & adaptive immunity, 
endothelial dysfunction ) 41,42,43 as shown in the image below. 
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ORGAN DYSFUNCTION IN SEVERE SEPSIS 
Sepsis exerts a detrimental effect on all the major organ systems in 
the body including the central nervous system, cardio vascular system, 
coagulation pathways, gastro intestinal system, renal system, respiratory 
system and the immune system. Presence of dysfunction of two or more 
organ systems is called Multi Organ Dysfunction Syndrome (MODS). 
The onset of MODS is associated with a very high mortality in the range 
of 30 – 75 % which can rise further upto 90% in the background of 
immune suppression , resistant organisms , advanced age and comorbid 
conditions44,45,46. 
 
SEPSIS --  MULTI ORGAN FAILURE 
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CARDIO VASCULAR SYSTEM 
In the year 1951, Waisbren et al first described the myocardial 
dysfunction in sepsis. The presence of reduced systemic resistance in 
sepsis initially masks the reduced myocardial contractility. But with 
progressive disease there is frank manifestation of the reduced stroke 
volume and ejection fraction. Onset of cardiovascular dysfunction in 
sepsis significantly increases its mortality rates.  The generalised vaso 
dilatation, increased capillary permeability and the   myocardial 
depression contribute to a state of tissue hypo perfusion which is reflected 
by the elevated lactate levels11. 
 
 
  
21 
 
RENAL SYSTEM 
Renal failure occurs in almost 20 % cases of severe sepsis. In fact 
sepsis is considered to be the most common cause of Acute Kidney Injury 
(AKI) in the intensive care setup. The conventional tools used in the 
detection of AKI namely urinary casts and fractional excretion of sodium 
are insufficient to make an early diagnosis of sepsis related AKI. This has 
prompted the use of novel bio markers namely Neutrophil Gelatinase 
Associated Lipocalin ( NGAL ), cystatin C, urinary interleukin 18 and 
Kidney injury molecule ( KIM 1 ). Some of these bio markers may even 
differentiate between septic AKI and non septic AKI. 
 
Sepsis produces AKI through various pathways like direct 
inflammatory insult, ischemia reperfusion injury, dysregulated 
coagulation, endothelial cell dysfunction and increased apoptosis. The 
increased levels of pro inflammatory substances in sepsis like TNF alpha, 
interleukins and interferons  exert a direct toxic effect on the glomerular 
cells and the renal tubular epithelium. The elevated levels of nitric oxide 
is responsible for the generalised vaso dilatation with secondary 
hypotension and activation of the  renin – angiotensin axis which triggers 
a intra renal vasoconstriction leading to fall in glomerular filtration rate. 
Also the Hypotension, intra vascular hypovolemia, renal vaso constriction 
and the cytokine storm result in acute tubular necrosis. Thus there is a 
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multi directional insult to the renal parenchyma necessitating an urgent 
renal replacement therapy49,50,51. 
 
Some of the treatment strategies in the treatment of sepsis related 
AKI are outlined below : 
 
• Volume repletion and vasopressor support to maintain a mean 
arterial pressure of atleast 65 mm Hg and a central venous pressure 
of 8-12 mm Hg 
• The vasopressors that have been found effective in septic shock are 
nor epinephrine and vasopressin. They have to be initiated as early 
as possible in septic shock 
• Tight glucose control using regular insulin 
• Fenoldopam , a dopamine agonist has been shown to improve renal 
blood flow and can be tried 
• Activated protein C can reduce the thrombin load and thus 
modulate the endothelial dysfunction 
• N acetyl cysteine and Atrial Natriuretic Peptide have been shown 
to have benefit in septic AKI 
• Novel therapeutic approaches include use of TLR inhibition , 
suppression of the inducible nitric oxide synthase pathways , 
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caspase inhibitors , lysophosphatidic acid and use of mesenchymal 
stem cells 
• Early initiation of extra corporeal purification of blood which has 
the added advantage of removal of excess cytokines 
• Hemofiltration , hemadsorption and renal assist devices have been 
tried52,53,54 
 
CENTRAL NERVOUS SYSTEM 
Many cases of severe sepsis develop a septic encephalopathy 
which may manifest as delirium, confusional states and coma. 
The factors contributing to the development of this septic 
encephalopathy include 
a) disruption of the blood brain barrier 
b) intra cranial hemorrhage (due to DIC) 
c) micro infarcts 
d) hypoxic encephalopathy 
e) cytokine excess and 
f) development of metastatic abcesses 
 
The septic encephalopathy can lead to long term residual 
neurological sequelae. These patients are also prone to develop critical 
illness polyneuropathy due to the sensori motor axonal degeneration and 
this entity is characterised by hypotonic limbs and diminished 
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reflexes55,56. The psychological impact of ICU stay in the form of 
depression and anxiety neuroses are also to be borne in mind. 
 
GASTRO INTESTINAL SYSTEM 
Severe sepsis results in hypotension which may result in reduced 
perfusion pressures in the splanchnic circulation thereby inducing liver 
dysfunction.  It can also cause bacterial translocation from the gut and 
endotoxemia. Usually these translocated bacteria and the bacterial 
products would be destroyed by the reticulo endothelial system of the 
liver57,58. But on account of the hepatic ischemia in sepsis these toxins 
directly enter the systemic circulation and exert their inflammatory 
effects. 
 
COAGULATION PATHWAYS 
An imbalance occurs between the pro thrombotic and anti 
thrombotic substances59,60 , as shown in the following picture 
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Coagulation pathways are more likely to be affected in gram 
negative sepsis where the endothelial dysfunction is more pronounce 
leading on to disseminated intravascular coagulation (DIC). This is a 
consumptive coagulopathy with presence of both thrombotic and 
hemorrhagic manifestations. It can predispose to the development of 
micro angiopathic  hemolytic anemia (MAHA) , acute renal failure and 
intra cranial hemorrhages and infarcts. 
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IMMUNE DYSFUNCTION 
Sepsis can dysregulate the immunological pathways through the 
cytokine storm thereby producing a state of relative immuno 
suppression61. 
 
CUTANEOUS MANIFESTATIONS 
Sepsis, either directly or via disseminated intra vascular 
coagulation can produce skin lesions like petechiae, purpurae, vesicles, 
blisters, necrosis and gangrene. The dermis is affected due to the 
disruption of its blood vessels by the micro thrombi. A cutaneous necrotic 
hemorrhagic lesion called purpura fulminans is particularly common in 
septicemia caused by Neisseria meningitidis and streptococcus 
pneumoniae. 
 
Musher said that there are mainly three patterns of involvement of 
the skin in Gram negative sepsis. 
1) Cellulitis and thrombophlebitis 
2) Ecthyma gangrenosum in cases of impaired inflammatory 
response due to neutropenia 
3) Symmetrical peripheral gangrene associated with 
disseminated intra vascular coagulation62. 
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Palpable petechiae and purpurae may also be due to 
leukocytoclastic vasculitis associated with organisms like Neisseria, 
pneumococci and staphylococcus aureus. A diffuse erythematous picture 
termed erythroderma may occur in toxic shock syndrome caused by 
staphylococcus aureus or streptococcus pyogenes. Desquamation of the 
skin may occur after two weeks. 
 
RESPIRATORY SYSTEM 
Often the earliest evidence of sepsis is hyperventilation with 
respiratory alkalosis. There is alveolar and interstitial fluid accumulation 
along with increase in the inflammatory cells and cytokines. This 
produces a disruption of the alveolar membrane. Also there is 
proliferation of the Type II pneumocytes which replaces the Type I cells 
with associated surfactant deficiency. Progressive alveolar exudates, 
interstitial fluid accumulation and the fibrotic changes  predispose to the 
Acute Respiratory Distress Syndrome (ARDS) 63. 
 
ARDS is characterised by the presence of the following components 
I. Onset of a lung injury within one week of the known clinical 
insult 
II. Bilateral opacities on chest X ray 
III. Absence of cardiac failure related fluid overload 
IV. Presence of hypoxemia 
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The term acute lung injury has been replaced by the newer Berlin 
definitions of varying grades of ARDS. This grading system is based on 
the pAO2 / FiO2 ratios. 
Thus ARDS is categorised as 
 
1. Mild ARDS    -  pAO2 / FiO2 :  200 to 300 
2. Moderate ARDS       -  pAO2 / FiO2 :  100 to 200 
3. Severe  ARDS            -  pAO2 / FiO2 :  < 100 
 
SEPSIS – ARDS PATHWAY 
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CHEST X RAY – ARDS 
 
 
INVESTIGATIONS TO BE DONE IN SEPSIS 
The investigations are done to assess the following factors 
1. Source of infection 
2. Severity of infection (especially the organ dysfunction) 
3. Causative micro organisms 
4. Prognostication 
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Firstly the basic investigations are done. The complete blood count 
shows evidence of sepsis in the form of leucocytosis or cytopenias. The 
serial monitoring of cell counts often gives an idea about the response to 
treatment. 
 
Typically these septic conditions have neutrophilic leucocytosis. 
However certain infections like typhoid , brucellosis , Rocky mountain 
spotted fever, ehrlichiosis etc may present with peripheral blood 
leukopenia64 . 
 
The liver function tests, renal function tests , coagulation profile 
and arterial blood gas analysis throw light on the presence and extent of 
organ dysfunctions. Often, unexplained hyperbilirubinemia, hyper 
lactatemia, metabolic acidosis, respiratory alkalosis or a 
thrombocytopenia are the earliest evidences of a septic process. Imaging 
modalities ( chest X ray, X ray- paranasal sinuses, ultrasound of abdomen 
, CT and MRI imaging of relevant areas , echocardiography ) are very 
useful in localising the source of infection. Cytokine and bio marker 
assay may be done if the facilities are available. 
 
Before starting the antibiotics blood cultures and cultures of 
relevant tissue or fluids ( including pus, sputum, CSF, urine, stool, bone 
marrow, skin lesions ) are  to be taken. The blood cultures are to be taken 
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from two or three different venipuncture sites. The volume of each blood 
culture sample should be atleast 23 – 30 ml.  These indicate the 
etiological agents involved and their drug sensitivities. Microscopic 
examination of the infected fluids or tissue samples  and staining with 
Gram stain / AFB stain may also be done. Molecular assays like the 
polymerase chain reaction methods are useful. 
 
Acute phase reactants like C Reactive Protein ( CRP ) , 
procalcitonin and the erythrocyte sedimentation rate ( ESR ) are useful in 
gauging the severity of sepsis and its response. Baseline serum cortisol 
and ACTH levels are useful in the diagnosis of critical illness associated 
adrenal insufficiency65,66,67,68. 
 
Assessment of the prognosis in severe sepsis is important to both 
the physician and the patients since they help in better decision making. 
Serum lactate levels and serum pro calcitonin are particularly useful in 
this regard. Prognostic scores have been developed based on some of the 
commonly used blood investigations and clinical parameters to guide the 
health care personnel. 
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DIFFERENTIAL DIAGNOSIS OF SEPSIS 
Many conditions  can produce a state of hypotension , raised body 
temperature and evidence of multi organ dysfunction and thus mimic 
sepsis. Some of these conditions are listed below :- 
1. Burns 
2. Trauma 
3. Adrenal insufficiency 
4. Pancreatitis 
5. Pulmonary embolism 
6. Occult internal bleed 
7. Cardiac tamponade 
8. Drug overdose or drug reaction 
9. Ruptured or dissecting aneurysm of aorta 
10. Thyroid storm 
11. Serotonin syndrome 
12. Heat stroke 
13. Anaphylaxis 
14. Post cardio pulmonary bypass 
15. Malignant hyperthermia69,70 
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MANAGEMENT OF SEPSIS 
INITIAL RESUSCITATION 
 
Adequate IV fluids have to be give to maintain targets of 
 
1. Central venous pressure 8-12 mm Hg 
2. Mean arterial pressure > 65 mm Hg 
3. Venous oxygen saturation > 70 % 
4. Urine output  > 0.5 ml / kg / hr 
5. Normalisation of lactate levels 
 
The best fluids for the initial resuscitation are crystalloids. An 
initial fluid challenge of about 15 – 30 ml / kg may be cautiously given. 
Further fluids may be given as per the hydration status , vitals and urine 
output. If the blood pressure fails to pick up despite adequate fluid 
resuscitation , vasopressors and inotropes are considered. Blood products 
may be transfused to maintain a hemoglobin concentration of atleast 7 to 
9 gm %. A platelet count of < 10,000 per cu mm warrants platelet 
transfusion. If surgery is contemplated a higher platelet count of around 
50,000 / cu mm is to be maintained71,72.73. 
 
The algorithm for the initial resuscitation in a case of severe sepsis 
is depicted in the following picture. 
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NUTRITIONAL SUPPORT 
Adequate calories should be replenished as per the body weight of 
the patient. Enteral route is to be preferred74,75. 
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ANTI BIOTICS 
Effective empirical anti microbial agents  against all of  the 
presumed causative organisms (bacterial , viral and fungal as per the 
clinical scenario) are to be started. The agents  that have good penetration 
into the tissues that are suspected to be the source of infection are chosen. 
Combination of empirical agents can be used especially in immuno 
compromised and neutropenic patients. The empirical therapy is given 
only till the availability of the culture sensitivity report after which the 
specific antbiotics are instituted. 
 
Ideally these antibiotics are given for a a period of  7 – 14 days. 
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AN ALGORITHM FOR ANTIBIOTIC PROTOCOL IN SEPSIS 
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SOURCE CONTROL 
The anatomical location of the source of infection is made out as 
early as possible. If it is a closed space infection, surgical removal of the 
infected tissues and fluids are to be considered. Any long standing 
indwelling vascular and other catheters are to be removed76,77.   
The doses and effects of important drugs used in the management 
of severe sepsis are mentioned in the following table. 
 
 
Key :  CO-cardiac output , MAP – mean arterial pressure ,  
SVR – systemic venous return 
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ROLE OF STEROIDS 
Severe sepsis with shock that is unresponsive to iv intra venous 
fluids and vasopressors may respond to parenteral hydro cortisone78. 
 
MANAGEMENT OF ARDS 
ARDS is ideally managed with mechanical ventilation with 
following points kept in mind 
1. A low tidal volume of around 6 ml / kg is preferred 
2. Plateau airway pressures should be < 30 cm H2O 
3. Higher PEEP is to be used to prevent alveolar collapse 
4. Recruitment manoeuvres and prone positioning have been 
reported to have improved outcomes in studies79 
 
GLYCEMIC STATUS 
A good glycemic status, targetting a sugar level of < 180 mg / dl is 
needed for a better  control of sepsis80,81 
 
DIALYSIS 
Since patients with severe sepsis are prone to develop acute kidney 
injury (AKI) at some point in the course of the disease , a renal 
replacement therapy will be needed82 
 
DVT PROPHYLAXIS 
Patients with severe sepsis should be treated with daily small dose 
of low molecular weight heparin to prevent the occuerrence of deep 
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venous thrombosis ( DVT ). Caution is to be exercised while prescribing 
these low molecular weight heparin to a patient with a creatinine 
clearance of < 30 ml/min. If the patient has documented hypersensitivity 
to heparin, other options like compression stockings , intermittent 
pneumatic compression devices etc may be considered83. 
 
STRESS ULCER PREVENTION 
Cases of severe sepsis should receive prophylaxis against the 
development of stress ulcers especially if there is a tendency to bleed. 
The proton pump inhibitors like pantoprazole are preferred to histamine 
receptor blockers in this regard. 
 
MONITORING THE ORGAN FUNCTION 
Throughout the course of treatment, the organ function parameters 
are to be monitored and this gives an idea about the severity of sepsis and 
also about the dose reduction of the medications. The following chart lists  
the parameters that are to be monitored during treatment84 
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RISK PROGNOSTICATION IN SEPSIS 
Many scoring systems have been developed to predict the severity, 
prognosis and risk of in-hospital mortality in critically ill patients 
including those suffering from severe sepsis. These models provide 
information regarding the degree of functional derangements in the 
various organs and the likelihood of serious morbidity and mortality. 
They usually have two parts – a score and a mortality assessment based 
on the score. The usual variables taken into account are age, 
comorbidities, functional derangements of organs , use of interventions 
and admission diagnosis.  Such prognostic scores enable the physicians 
and hospital  administrators  to improve their decision making skills. 
They also help in better allocation of hospital resources85,86,87. 
 
Some of these scores are 
1. APACHE II   {Acute Physiology and Chronic Health 
Evaluation }  Score 
2. SAPS  { Simplified Acute Physiology } Score 
3. SOFA  {Serial Organ Failure Assessment }  Score 
4. MPM { Mortality Prediction Model} 
 
Based on their development , these scoring systems may be 
categorised into generations as shown below 
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Usually the data that are objective, highly reproducible and those 
that are easy to measure are used in these scoring systems. Based on these 
data and associated equations the risk scores are calculated and then the 
patients may be stratified into varying levels of risk groups. 
 
There are five important uses of such scoring systems 
i. To measure the severity of disease and thereby enable the health 
care providers to make decisions regarding resource allocation 
ii. The ICU performances of various ICU s can be compared using 
these scoring systems 
iii. Such scores are utilised in randomised controlled trials 
iv. The prognosis can be explained to patient relatives objectively 
v. These are also used to assess whether the patient is suitable for 
novel therapeutic measures. 
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REQUISITES FOR A GOOD PROGNOSTIC SCORING SYSTEM 
 
A good scoring system must be 
 Simple 
 Easy to use 
 Universally applicable 
 Reliable and consistent 
 Good sensitivity and specificity 
Of the various scoring systems that are used in the critically ill 
patients , there are two that have been tested in many studies and found to 
be effective prognosticatory tools. They are the APACHE II and SOFA 
scores. 
 
APACHE II SCORE 
The APACHE II or the Acute Physiology And Chronic Health 
Evaluation Score was first developed by the US researchers led by Knaus 
et al. The model has been upgraded thrice following British and Irish 
studies and thus APACHE I , II and III are available. Of these the 
APACHE II has the advantages of simplicity and effectiveness. This 
score ranges from 0 to 71 and includes weightage for age , past comorbid 
conditions and acute physiological parameters88. The following 12 
parameters are to be taken within the first 24 hours of  presentation  
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i. Temperature 
ii. Mean arterial pressure 
iii. Heart rate 
iv. Respiratory rate 
v. pAO2 
vi. arterial pH or serum bicarbonate 
vii. serum potassium 
viii. serum sodium 
ix. serum creatinine 
x. hematocrit 
xi. white blood cell count 
xii. Glasgow coma scale 
In general the following cases are not to be scored using the 
APACHE II system 
• Age of admission  < 16 years 
• Duration of stay in the ward < 8 hours 
• If the admission is for primary burns 
• Admission following coronary bypass grafting 
• If the twelve variables within first 24 hours are not available 
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The method of calculation of the APACHE II score is shown in the 
subsequent table. 
APACHE II SCORE CALCULATION CHART 
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SOFA SCORE 
The SOFA or Serial Organ Failure Assessment score is used to 
monitor the physiological status of a critically ill patient. It provides a 
picture of the functioning of the organ systems and the rate of failure of 
the organ89s. It is the summation of six different scores , each of which 
represents an organ system. The organs taken into account for the 
calculation of SOFA score are as follows : 
a) Respiratory system 
b) Cardio vascular system 
c) Liver 
d) Coagulation 
e) Renal system 
f) Central nervous system 
The method of calculation of SOFA score is depicted in the 
following table 
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SOFA SCORE CALCULATION CHART 
 
 
 
The SOFA score can be calculated on serial days and the highest 
SOFA score as well as mean SOFA score may be assessed. A rise in the 
SOFA score in the first 24 – 48 hours indicates higher risk of mortality. 
This score is especially useful in the serial monitoring and 
prognostication of patients with severe sepsis. 
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Many studies have been conducted to validate the usefulness of 
these prognostication criteria. Some of the studies have compared 
different scoring systems and assessed their effectiveness. 
 
Our study is aimed at comparing two of the most important among 
these systems – namely the APACHE II score and the SOFA score in the 
setting of Sepsis – Multi Organ Dysfunction Syndrome.  
 
 
 
 
 
 
 
  
 
MATERIALS  
AND  
METHODS 
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MATERIALS AND METHODS 
 
Aim And Objectives 
To determine and compare APACHE II score and SOFA score as 
predictors of mortality in patients admitted with sepsis and MODS. 
 
Study Centre  
Institute of Internal Medicine, Madras Medical  College and Rajiv 
Gandhi Govt General Hospital, Chennai 
 
Duration of Study   
6 months 
 
Study Design 
Observational Study ( prospective and retrospective ) 
 
Sample Size 
60 patients 
 
Inclusion Criteria 
1 .Patients above 18 years of age 
2. Patients with evidence of sepsis and MODS on admission 
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Exclusion Criteria 
1. Patients being treated with immunosuppressant medications 
2. Patients having retro viral infection 
3. Ante natal patients 
 
Data Collection and Methods 
Patients are subjected to history taking ,  clinical examination and 
relevant laboratory investigations are done. 
 
Materials and Methods 
Patients admitted with sepsis and MODS are  selected for clinical 
study as per inclusion / exclusion criteria. They   are subjected to routine 
blood tests like complete hemogram, renal function tests, serum 
electrolytes, liver function test  and arterial blood gas analysis. In relevant 
cases imaging studies (USG) and fever profile (blood, urine C/S, 
WIDAL, MSAT, IgM dengue )  are evaluated. 
These are done to ascertain the presence of Sepsis – MODS. 
History regarding the clinical presentation, comorbidities are recorded. 
Clinical examination will be done. Use of any inotropes, ventilatory 
support, dialytic interventions are noted as the SOFA score includes them 
for scoring purposes.  APACHE II score is calculated within the first 24 
hours. SOFA score is calculated on day 1 and day 3 and the mean SOFA 
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score is calculated. Patients are followed up for outcome in terms of 
recovery or mortality at 30 days. 
 
Procedure / Investigation Details 
1. Hematocrit 
2. White blood cell count 
3. Platelet count 
4. Sr creatinine 
5. Sr bilirubin 
6. Arterial blood gas analysis 
7. Sr electrolytes 
8. Blood , urine C/S 
9. Smear for Mp 
10. WIDAL 
11. MSAT & 
12. IgM dengue   
13. Chest xray  
14. USG abdomen (all above workup are to  ascertain sepsis  
– MODS  ) 
 
Analysis Plan 
SPSS, Epi INFO softwares 
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OBSERVATION AND RESULTS 
 
FLOW CHART OF THE METHODOLOGY 
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30 DAY MORTALITY RATES  IN SEPSIS –  
MODS IN OUR  STUDY 
 
  
 
NUMBER 
 
PERCENTAGE 
 
SURVIVED 
 
38 
 
63.30% 
 
 
DIED 
 
22 
 
36.60% 
 
 
TOTAL 
 
60 
 
100% 
 
 
 
In our study the mortality rates in patients with Sepsis – Multi 
Organ Dysfunction Syndrome was found to be 36.6 % which is consistent 
with several national and international studies which estimate the death 
rate at 30 – 80 %. 
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PIE CHART DEPICTING THE MORTALITY IN SEPSIS MODS 
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AGE WISE DISTRIBUTION OF  SURVIVORS AND NON 
SURVIVORS 
 
 
 
AGE 
GROUP 
 
NUMBER 
OF 
PATIENTS 
 
SURVIVED 
 
DIED 
 
MORTALITY  
PERCENTAGE 
 
 
20 – 30 
 
5 
 
2 
 
3 
 
60 % 
 
 
30- 40 
 
12 
 
9 
 
3 
 
25% 
 
 
40 – 50 
 
10 
 
5 
 
5 
 
50 % 
 
 
50 – 60 
 
13 
 
8 
 
5 
 
22.70 % 
 
 
60 – 70 
 
13 
 
11 
 
2 
 
38.50 % 
 
 
70 – 80 
 
6 
 
3 
 
3 
 
50 % 
 
 
> 80 
 
1 
 
0 
 
1 
 
100 % 
 
 
The majority of deaths were in patients aged above 40 years . 
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BAR DIAGRAM SHOWING THE AGE WISE DISTRIBUTION OF 
SURVIVORS AND NON SURVIVORS 
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AGE  --  AS A RISK FACTOR FOR MORTALITY  
IN SEPSIS - MODS 
 
PARAMETER 
 NON SURVIVORS 
T 
SCORE P VALUE 
SURVIVORS 
 
MEAN 
 
STANDARD MEAN 
 
STANDARD 
DEVIATION 
 
DEVIATION 
 
 
 
 
AGE 
 
 
 
53.02 14.54 51.72 17.53 0.30 0.38 
 
The p value being > 0.5 indicates that in our study, the age 
difference between the survivor group and non survivor group was not 
significant. 
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SEX WISE DISTRIBUTION OF  SURVIVORS AND NON 
SURVIVORS 
 
 
MALE 
 
FEMALE 
 
TOTAL 
 
SURVIVED 
 
DIED 
 
TOTAL 
 
 
SURVIVED 
 
DIED 
 
 
31 
 
22 
 
9 
 
29 
 
16 
 
13 
 
 
Thus the mortality is noted to be  
 29.03 % in males and 
 44.8 %  in females 
 
 
The mortality rates appear to be higher in females than in males. 
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BAR DIAGRAM SHOWING THE SEX WISE DISTRIBUTION OF 
SURVIVORS AND NON SURVIVORS 
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APACHE II SCORE AND ITS CORRELATION WITH 30 DAY 
MORTALITY 
 
PARAMETER 
 NON SURVIVORS 
T 
SCORE 
P 
VALUE 
SURVIVORS 
 
MEAN 
 
STANDARD MEAN 
 
STANDARD 
DEVIATION 
 
DEVIATION 
 
 
APACHE II 
SCORE 
 
16.81 4.52 25.63 5.78 6.44 < 0.05 
 
 
P value is significant, implying that APACHE II score ( which is 
measured in the first 24 hours ) is a good predictor of 30 day mortality in 
patients admitted  with sepsis – MODS.  
 
The average APACHE II score is noted to be around 16  in 
survivors but much higher in non survivors ( 25 )  
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BAR DIAGRAM SHOWING THE CORRELATION BETWEEN 
APACHE II SCORE AND 30 DAY MORTALITY 
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SOFA I  SCORE AND ITS CORRELATION WITH 30 DAY 
MORTALITY 
 
 
PARAMETER 
 NON SURVIVORS 
T 
SCORE 
P 
VALUE 
SURVIVORS 
 
MEAN 
 
STANDARD MEAN 
 
STANDARD 
DEVIATION 
 
DEVIATION 
 
 
 
SOFA I 
SCORE 
 
 
5.18 1.90 10.68 1.86 9.44 < 0.05 
 
 
SOFA I score refers to the Serial Organ Failure Assessment score 
derived on the first day of admission. 
 
The above chart shows that SOFA I score has a definite correlation 
with mortality, since the p value is less than 0.05.  
 
The average SOFA 1 score in survivors is noted to be around 5 
while that in non survivors is 10, implying that higher the SOFA 1 score 
– higher is the mortality. 
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BAR DIAGRAM SHOWING CORRELATION BETWEEN SOFA I 
SCORE AND MORTALITY 
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SOFA III SCORE AND ITS CORRELATION WITH MORTALITY 
IN SEPSIS – MODS 
 
PARAMETER 
 NON SURVIVORS 
T 
SCORE 
P 
VALUE 
SURVIVORS 
 
MEAN 
 
STANDARD MEAN 
 
STANDARD 
DEVIATION 
 
DEVIATION 
 
 
SOFA III 
SCORE 
 
5.44 1.99 12.09 1.62 13.65 < 0.05 
 
 
Among the twenty two deaths, five had occurred within the first 
two days and hence the third day SOFA value ( SOFA III ) could not be 
obtained. 
 
Leaving out these five  cases, the SOFA III score was calculated 
for the remaining 55 patients in the study group and its correlation with 
mortality was assessed 
 
As the chart shows the P value was noted to be significant, 
implying that a higher SOFA III Score is a predictor of mortality 
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BAR DIAGRAM SHOWING CORRELATION BETWEEN SOFA 
III SCORE AND MORTALITY 
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MEAN SOFA SCORE AND ITS CORRELATION WITH 
MORTALITY IN  SEPSIS – MODS 
 
PARAMETER 
 NON SURVIVORS 
T 
SCORE 
P 
VALUE 
SURVIVORS 
 
MEAN 
 
STANDARD MEAN 
 
STANDARD 
DEVIATION 
 
DEVIATION 
 
 
 
MEAN SOFA 
SCORE 
 
 
5.63 1.9 11.38 1.66 11.55 < 0.05 
 
 
Among  the patients,  for whom a day 1 and day 3 SOFA scores 
were available , the mean of those two scores were calculated and 
assessed 
 
The p value was significant 
 
Hence a higher mean SOFA score indicates a higher probability of 
death 
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BAR DIAGRAM SHOWING CORRELATION BETWEEN MEAN 
SOFA SCORE AND MORTALITY 
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RECTAL TEMPERATURE AND ITS CORRELATION WITH 
MORTALITY 
 
 
PARAMETER 
 NON SURVIVORS 
T 
SCORE 
P 
VALUE 
SURVIVORS 
 
MEAN 
 
STANDARD MEAN 
 
STANDARD 
DEVIATION 
 
DEVIATION 
 
 
RECTAL 
TEMPERATURE 
 
In degrees Celsius 
 
38.2 0.69 38.03 0.91 0.77 0.21 
 
 
Here the p value is greater than 0.05 , indicating that rectal 
temperature has no independent correlation with mortality in patients 
with sepsis – MODS 
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BAR DIAGRAM SHOWING THE MEAN RECTAL 
TEMPERATURE IN SURVIVORS AND NON SURVIVORS 
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HEART RATE AND ITS CORRELATION WITH MORTALITY 
 
PARAMETER 
 NON SURVIVORS 
T 
SCORE P VALUE 
SURVIVORS 
 
MEAN 
 
STANDARD MEAN 
 
STANDARD 
DEVIATION 
 
DEVIATION 
 
 
 
HEART RATE 
 
 
103.6 22.6 124.3 23.2 3.3 < 0.05 
 
There was a positive correlation between heart rate and mortality  
(p < 0.0.5 ) 
 
The mean heart rate in survivors was 103 while that in non 
survivors was noted to be higher - 124 
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BAR DIAGRAM SHOWING THE MEAN HEART RATE  IN 
SURVIVORS AND NON SURVIVORS 
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RESPIRATORY RATE AND ITS CORRELATION WITH 
MORTALITY 
 
PARAMETER 
 NON SURVIVORS 
T 
SCORE 
P 
VALUE 
SURVIVORS 
 
MEAN 
 
STANDARD MEAN 
 
STANDARD 
DEVIATION 
 
DEVIATION 
 
 
 
RESPIRATORY 
RATE 
 
 
23.3 7.5 32.7 7.8 4.6 < 0.05 
 
 
The mean respiratory rate in non survivors was found to be higher 
in non survivors than in survivors and the p value was also less than 0.05 
, suggesting that a higher respiratory rate has an independent correlation 
with mortality in sepsis – MODS. 
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DIAGRAM SHOWING THE MEAN  RESPIRATORY RATE  IN 
SURVIVORS AND NON SURVIVORS 
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PaO2 AND  ITS CORRELATION WITH MORTALITY 
 
PARAMETER 
 NON SURVIVORS 
T 
SCORE 
P 
VALUE 
SURVIVORS 
 
MEAN 
 
STANDARD MEAN 
 
STANDARD 
DEVIATION 
 
DEVIATION 
 
 
 
PaO2 
 
In mm Hg 
 
69.7 11.26 66.8 11.17 0.94 0.17 
 
 
PaO2  refers to the partial pressure of arterial oxygen. When its 
values were compared between the survivor group and the non survivor 
group, it was found that there was no significant relationship between 
PaO2 and mortality ( p value is 0.17 and a value >0.05 is taken as 
insignificant correlation). 
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BAR DIAGRAM SHOWING THE MEAN  PARTIAL PRESSURE  
OF ARTERIAL OXYGEN  IN SURVIVORS AND NON 
SURVIVORS 
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pH AND  ITS CORRELATION WITH MORTALITY 
 
PARAMETER 
 NON SURVIVORS 
T 
SCORE P VALUE 
SURVIVORS 
 
MEAN 
 
STANDARD MEAN 
 
STANDARD 
DEVIATION 
 
DEVIATION 
 
 
 
pH 
 
 
7.42 0.1 7.38 0.1 1.4 0.08 
 
 
The pH of blood does not show any direct relationship with 
survival as evidenced by a p value of more than  0.05. 
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BAR DIAGRAM SHOWING THE AVERAGE VALUES OF   pH   
IN SURVIVORS AND NON SURVIVORS 
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SERUM SODIUM AND  ITS CORRELATION WITH 
MORTALITY 
 
PARAMETER 
 NON SURVIVORS 
T 
SCORE 
P 
VALUE 
SURVIVORS 
 
MEAN 
 
STANDARD MEAN 
 
STANDARD 
DEVIATION 
 
DEVIATION 
 
 
 
SERUM 
SODIUM 
 
 
142 9.73 146.9 7.4 1.97 0.02 
 
 
Serum  sodium, thus has an average value of 142 in survivors and 
146 in non survivors. Since the p value is less than 0.05 , this indicates a 
significant correlation. 
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BAR DIAGRAM SHOWING THE MEAN  SERUM SODIUM  
VALUES IN SURVIVORS AND NON SURVIVORS 
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SERUM POTASSIUM AND  ITS CORRELATION WITH 
MORTALITY 
 
PARAMETER 
 NON SURVIVORS 
T 
SCORE P VALUE 
SURVIVORS 
 
MEAN 
 
STANDARD MEAN 
 
STANDARD 
DEVIATION 
 
DEVIATION 
 
 
 
SERUM 
POTASSIUM 
 
 
3.92 0.9 3.63 1.6 0.87 0.19 
 
 
The serum potassium value does not correlate with mortality in 
patients with Sepsis – MODS. 
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BAR DIAGRAM SHOWING THE CORRELATION BETWEEN 
SERUM POTASSIUM AND MORTALITY 
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SERUM CREATININE AND  ITS CORRELATION WITH 
MORTALITY 
 
PARAMETER 
 NON SURVIVORS 
T 
SCORE 
P 
VALUE 
SURVIVORS 
 
MEAN 
 
STANDARD MEAN 
 
STANDARD 
DEVIATION 
 
DEVIATION 
 
 
 
SERUM 
CREATININE 
 
 
1.33 0.62 2.5 1.21 4.84 P < 0.05 
 
 
Since the p value is less than 0.05 , there is a definite correlation 
between increased creatinine and mortality risk in patients with Sepsis – 
MODS. 
 
The average value of creatinine is found to be higher in non 
survivors  than non survivors ( 2.5 Vs 1.33 ) 
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BAR DIAGRAM SHOWING THE CORRELATION BETWEEN 
SERUM CREATININE  AND MORTALITY 
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HEMATOCRIT AND ITS CORRELATION WITH MORTALITY 
 
PARAMETER 
 NON SURVIVORS 
T 
SCORE 
P 
VALUE 
SURVIVORS 
 
MEAN 
 
STANDARD MEAN 
 
STANDARD 
DEVIATION 
 
DEVIATION 
 
 
 
HEMATOCRIT 
 
 
44.9 7.14 46.2 6.8 0.69 0.24 
 
 
Hematocrit does not exhibit any definitive correlation with 
mortality in our study ( p = 0.24 ) 
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BAR DIAGRAM SHOWING THE AVERAGE HEMATOCRIT 
VALUES IN SURVIVORS AND NON SURVIVORS 
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TOTAL LEUKOCYTE COUNT AND  ITS CORRELATION WITH 
MORTALITY 
 
 
PARAMETER 
 NON SURVIVORS 
T 
SCORE 
P 
VALUE 
SURVIVORS 
 
MEAN 
 
STANDARD MEAN 
 
STANDARD 
DEVIATION 
 
DEVIATION 
 
 
 
TOTAL 
LEUKOCYTE 
COUNT 
 
 
12,944 5977 11,686 4909 0.82 0.20 
 
 
The total leukocyte count does not appear to have independent 
direct correlation with mortality in patients with Sepsis – MODS. 
 
 
 
 
 
 
 
 
87 
 
 
BAR DIAGRAM SHOWING THE MEAN LEUKOCYTE COUNTS 
IN SURVIVORS AND NON SURVIVORS 
 
 
 
 
 
 
88 
 
GLASGOW COMA SCALE AND  ITS CORRELATION WITH 
MORTALITY 
 
PARAMETER 
 NON SURVIVORS 
T SCORE P VALUE 
SURVIVORS 
 
MEAN 
 
STANDARD MEAN 
 
STANDARD 
DEVIATION 
 
DEVIATION 
 
 
 
GLASGOW 
COMA SCALE 
 
 
12.9 2 9.7 2.3 5.6 < 0.05 
 
Glasgow coma scale has an independent correlation with mortality 
in sepsis – MODS in our study. 
 
A lower GCS appears to be associated with a higher mortality risk 
 
The mean GCS in survivors was 13 while that in non survivors was 
much lower at  9 
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BAR DIAGRAM SHOWING THE AVERAGE GLAGOW COMA 
SCALE  IN SURVIVORS AND NON SURVIVORS 
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SERUM BILIRUBIN AND  ITS CORRELATION WITH 
MORTALITY 
 
 
PARAMETER 
 NON SURVIVORS 
T 
SCORE 
P 
VALUE 
SURVIVORS 
 
MEAN 
 
STANDARD MEAN 
 
STANDARD 
DEVIATION 
 
DEVIATION 
 
 
 
SERUM 
BILIRUBIN 
 
 
1.4 0.54 4.02 3.3 4.64 < 0.05 
 
Serum bilirubin , which is one of the variables taken into account 
in the calculation of the SOFA score is found to have a positive 
correlation with mortality in our study. 
 
The mean total bilirubin was higher in the mortality group than 
among the survivors ( 4 Versus 1.4 ) 
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BAR DIAGRAM SHOWING THE AVERAGE SERUM 
BILIRUBIN IN SURVIVORS AND NON SURVIVORS 
 
 
 
 
 
 
 
 
 
 
 
92 
 
 
PLATELET COUNT AND  ITS CORRELATION WITH 
MORTALITY 
 
 
PARAMETER 
 NON SURVIVORS 
T 
SCORE 
P 
VALUE 
SURVIVORS 
 
MEAN 
 
STANDARD MEAN 
 
STANDARD 
DEVIATION 
 
DEVIATION 
 
 
 
PLATELET 
COUNT 
 
 
124973 67000 106700 49900 1.09 0.13 
 
 
The platelet count does not exhibit any definitive correlation with 
mortality in our study ( p = 0.13 ) 
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BAR DIAGRAM SHOWING THE AVERAGE PLATELET 
COUNTS IN SURVIVORS AND NON SURVIVORS 
 
 
 
 
 
 
 
 
 
  
 
 
DISCUSSION 
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DISCUSSION 
 
This study was conducted as a prospective and retrospective 
observational study in patients admitted with Sepsis – Multi organ 
Dysfunction Syndrome in the intensive medical  care wards of Madras 
Medical College and Rajiv Gandhi Government General Hospital. The 
sample size was 60. After getting the informed consent of the patients and  
their  attending close relatives , the patients were subjected to history 
taking, physical examination and relevant laboratory testing and imaging. 
These were done to ascertain the presence of sepsis and multi organ 
dysfunction in the patient. 
 
Sepsis – Multi organ dysfunction syndrome is a major cause of 
mortality in India and worldwide. Hence a better understanding of its 
etiopathogenesis and the disease course is necessary. Further, the 
application of prognostication tools like the APACHE II score and the 
SOFA score aid in assessing the prognosis and help the care givers in 
making improved decisions.  
 
APACHE II score has shown good correlation with several critical 
care states, including Sepsis – multi organ dysfunction syndrome. Several 
studies have been conducted to compare its effectiveness against the other 
95 
 
newly developed scoring systems like SOFA and the SAPS score. Some 
studies have supported APACHE II while others concluded that SOFA 
was better. 
 
A study by Q Qiao et al comparing the APACHE 2 and SOFA 
score in critically ill elderly patients showed that SOFA had a better 
predictive capacity of mortality than APACHE 290. 
 
Another study by K.S. Abinandan et al also showed that serial 
SOFA was a better mortality indicator in cases of sepsis and MODS91. 
  
However studies by K.M. Ho, K.Y. Lee et al showed that 
APACHE II score was a better predictor of mortality than SOFA score92 
 
 In our study both the scores were compared with each other and 
their component variables were also evaluated as individual predictors of 
mortality. 
 
The APACHE II score was shown to have good correlation with 
mortality in cases of Sepsis – Multi organ Dysfunction syndrome. A 
higher APACHE II score was associated with mortality. 
 
The SOFA scores ( SOFA I , SOFA III and mean SOFA ) were all 
noted to have good predictive correlation  with  mortality. These scores 
were noted to be higher in the non survivor group.  All three showed a p 
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value of less than 0.05. However the lowest absolute value of p was noted 
in  SOFA III. Also, in the survivor group the day 1 SOFA score was low 
and it further reduced on day 3. But among the non survivors the day 1 
SOFA score itself was higher and this increased further on day 3. This 
indicates that probably a daily monitoring of the SOFA score is more 
important than a single value and that progressively  increasing  score is 
more predictive of mortality than absolute values. 
 
Apart from these scores, some of their component variables namely 
the heart rate, respiratory rate, serum sodium, serum creatinine,  Glasgow 
coma scale and  serum  bilirubin were also noted to have significant ( p < 
0.05 ) correlation with mortality in sepsis – MODS. 
 
However pAO2 , pH , hematocrit , platelet count and total WBC 
count did not show any correlation with mortality. 
 
  
  
 
 
CONCLUSION 
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CONCLUSION 
 
Both the APACHE II score and  SOFA scores ( SOFA I , SOFA III 
and the mean SOFA scores ) were noted to have significant correlation 
with 30 day mortality in cases of sepsis – multi organ dysfunction 
syndrome. 
 
Higher values of APACHE 2, SOFA 1 , SOFA 3 scores were 
associated with higher mortality  
 
A serial monitoring of SOFA scores on consecutive days is a better 
prognostication tool than a single value. A rising SOFA score on 
subsequent days is likely to be associated with higher mortality risk. 
 
Heart rate, respiratory rate , serum sodium, serum creatinine ,  
Glasgow coma scale and  serum  bilirubin were also noted to have 
independent correlation with mortality in these patients. 
` 
  
  
 
 
LIMITATIONS 
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LIMITATIONS OF THE STUDY 
 
A multi centric study with a larger sample size and longer follow 
up is essential to assess the predictive power of these prognostication 
tools in a more comprehensive manner. 
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COMPARATIVE ANALYSIS OF APACHE-II SCORE AND SOFA 
SCORE AS PREDICTORS OF MORTALITY IN PATIENTS 
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